Altimmune Inc (ALT)

11.26 -0.44 (-3.76%)
Closed USD Disclaimer
10.87 -0.39 (-3.46%)

Altimmune Inc Company Profile

Industry
Biotechnology
Sector
Healthcare
Employees
47
Equity Type
ORD
Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Contact Information
Address
Gaithersburg,20878 United States
Phone
240 654 1450
Fax
-
Top Executives
Name
Age
Since
Title
Wayne F. Pisano 66 2018 Independent Director
David J. Drutz 82 2011 Independent Director
Mitchel B. Sayare 73 2010 Independent Chairman
John Petricciani 85 0000 Member of Scientific Advisory Board
Diane Kathryn Jorkasky 69 2020 Independent Director
Richard James Whitley 75 0000 Member of Scientific Advisory Board
Philip L. Hodges 52 2017 Independent Director
Klaus O. Schafer 71 2012 Independent Director
John M. Gill 69 2004 Independent Director
Vipin K. Garg 63 2018 President, CEO & Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.